Revenue Update on Digirad Corporation(NASDAQ:DRAD)

Digirad Corporation(NASDAQ:DRAD) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during Pre-market on Jul 28, 2016. Company reported revenue of $32.09M. Analysts estimated a revenue of $32.78M. Earnings per share were $0.09. Analysts had estimated an EPS of $0.09.

Digirad Corporation (DRAD) shares turned negative on Thursdays trading session with the shares closing down -0.11 points or -2.03% at a volume of 27,152. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $5.5. The peak price level was also seen at $5.5 while the days lowest was $5.31. Finally the shares closed at $5.32. The 52-week high of the shares is $6.92 while the 52-week low is $3.5. According to the latest information available, the market cap of the company is $104 M.

Several Insider Transactions has been reported to the SEC. On Jun 10, 2016, Virgil Lott (President, Diagnostic Imaging) sold 23,333 shares at $5.25 per share price.Also, On Jun 9, 2016, Jeffrey E. Eberwein (director) purchased 1,846 shares at $4.99 per share price.On Jun 1, 2016, Matthew G. Molchan (President and CEO) sold 5,833 shares at $5.01 per share price, according to the Form-4 filing with the securities and exchange commission.

Digirad Corporation is a provider of diagnostic solutions. The Company’s business is organized into two segments: Diagnostic Services and Diagnostic Imaging. The Company provides in-office nuclear cardiology and ultrasound imaging services and also provides cardiac event monitoring services to physician practices hospitals and imaging centers through its Diagnostic Services business segment. The Company sells medical diagnostic imaging systems including solid-state gamma cameras for nuclear cardiology and general nuclear medicine applications as well as provides service on the products it sells through its Diagnostic Imaging business segment. The Company’s imaging systems are sold in both portable (movable) and fixed (stationary) configurations which include Cardius XPO Cardius X-ACT and ergo gamma cameras.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Digirad Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on Digirad Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.